U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06892678) titled 'DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma' on March 19.
Brief Summary: The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Osteosarcoma Recurrent
Ewing's Tumor Recurrent
Intervention:
DRUG: DFMO
DFMO dose will be calculated based on the BSA measured within 14 days prior to the beginning of each cycle. Tablets may be swallowed whole, chewed, or crushed and mixed ...